APT(SH:688617) Sou Hu Cai Jing·2026-02-10 00:50Core Viewpoint - The financial performance of Huitai Medical (688617) shows significant growth in revenue and net profit, indicating a strong position in the medical device industry focused on electrophysiology and vascular intervention [3]. Financial Performance - For the first three quarters of 2025, Huitai Medical reported a main revenue of 1.867 billion yuan, a year-on-year increase of 22.47% [3]. - The net profit attributable to shareholders reached 623 million yuan, up 18.02% year-on-year [3]. - The third quarter alone saw a main revenue of 654 million yuan, reflecting a 24.77% increase compared to the same quarter last year [3]. - The net profit for the third quarter was 198 million yuan, with a year-on-year growth of 6.77% [3]. - The company maintained a gross profit margin of 73.19% [3]. Financing and Trading Activity - On February 9, 2026, Huitai Medical's stock closed at 229.38 yuan, with a trading volume of 7315 hands and a total transaction amount of 167 million yuan [1]. - The net inflow of main funds was 12.89 million yuan, accounting for 7.71% of the total transaction amount, while retail investors saw a net outflow of 1.67 million yuan [1]. - The financing data indicated a net financing purchase of 3.12 million yuan on the same day, with a total financing balance of 181 million yuan [2]. Institutional Ratings - In the last 90 days, four institutions provided ratings for Huitai Medical, with three giving a "buy" rating and one an "increase" rating [4].